ATLANTA, May 22, 2024--Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
ATLANTA, May 14, 2024--Alzamend Neuro Announces Initial Closing of Private Placement; Investor Purchase Up to $25 Million of Preferred Shares; Proceeds for Clinical Trials
ATLANTA, May 09, 2024--Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of Up to $25 Million